Trial Profile

Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant Chemotherapy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertuzumab (Primary) ; Sargramostim (Primary) ; TPIV 100 (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
Focus Therapeutic Use

07 Jun 2022 Currently, 20 patients in the run-in phase have been enrolled. Enrollment to the randomized phase II portion is expected to begin in March 2022 as per trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology
07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology
20 Feb 2020 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com